{
    "nct_id": "NCT04577014",
    "official_title": "A Multi-cohort Study of Retifanlimab With or Without Gemcitabine and Docetaxel in Patients With Advanced Sarcoma",
    "inclusion_criteria": "* Diagnosis of metastatic or locally advanced and unresectable high-grade soft tissue sarcoma. Unresectable is defined as:\n\n  1. primary tumor cannot be safely removed surgically, or\n  2. primary tumor would benefit from systemic therapy prior to a surgical approach\n* Be willing and able to provide written informed consent\n* Must consent to mandatory tumor biopsy (if deemed safe and feasible) for research studies at screening, if archival tissue is not available, and at C1D15, C3D15.\n* Age ≥ 18 years\n* ECOG performance status ≤ 1\n* Presence of measurable disease per RECIST v1.1\n\n  * Target lesions must not be chosen from a previously irradiated field unless there has been radiographically and/or pathologically documented tumor progression in that lesion prior to enrollment.\n* No prior systemic therapy (see exclusion criteria, below)\n* Negative serum pregnancy test in women of childbearing potential\n* Patients with chronic HBV (HBsAg-positive with undetectable or low HBV DNA and normal ALT, or HBsAg-negative with anti-HBc-positive serology) and HCV (completed curative antiviral treatment with HCV viral load below the limit of quantification) may be eligible\n\n  * Patients with HBV should be treated with suppressive antiviral therapy prior to enrollment\n  * Patients with HCV must have completed curative therapy and have negative HCV viral load\n* Adequate organ function, as defined in Table 2:\n\nTable 2: Laboratory Parameters Required for Study Inclusion\n\nHematological Absolute neutrophil count (ANC): ≥ 1,500 /mcL Platelets: ≥ 75,000 / mcL Hemoglobin: ≥ 9g/dL or ≥ 5.6 mmol/L\n\nRenal Serum creatinine: ≤ 1.5 X upper limit of normal (ULN) OR Measured or calculated creatinine clearance: ≥ 60 mL/min for patient with creatinine levels > 1.5 X institutional ULN (GFR can also be used in place of creatinine orCrCl)\n\nHepatic Serum total bilirubin: ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for patients with total bilirubin levels > 1.5 ULN except patients with Gilbert's disease (≤ 3x ULN) AST (SGOT) and ALT (SGPT): ≤ 2.5 X ULN OR ≤ 5 X ULN for patients with liver metastases\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Received any systemic therapy in the advanced or metastatic setting\n\n  * Adjuvant or neoadjuvant therapies received ≥ 1 year prior to enrollment are permitted\n* Unstable or deteriorating cardiovascular disease within the previous 6 months, including:\n\n  * Unstable angina or myocardial infarction\n  * CVA/stroke\n  * New York Heart Association [NYHA] Class III or IV congestive heart failure\n  * Uncontrolled clinically significant arrhythmias\n* Current use of immunosuppressive medication, EXCEPT for the following:\n\n  * Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection)\n  * Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent\n  * Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n* Evidence of clinically significant immunosuppression such as the following:\n\n  * Primary immunodeficiency state such as Severe Combined Immunodeficiency Disease\n  * Concurrent opportunistic infection\n  * Receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid doses > 10 mg/day of prednisone or equivalent within 2 months prior to enrollment\n* History or evidence of symptomatic autoimmune disease in past 2 years prior to enrollment.\n\n  * Replacement therapy (e.g., thyroxine for hypothyroidism, insulin for diabetes or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment for autoimmune disease\n* Uncontrolled HIV infection, as defined by one or more of the following:\n\n  * Patients with CD4+ T-cell (CD4+) counts < 350 cells/uL\n  * Patients with a history of an opportunistic infection secondary to AIDS\n  * Patients on anti-microbials with drug-drug interactions with the study drugs on this protocol, who cannot be switched to alternative anti-microbials\n  * Patients on antiretroviral therapy < 4 weeks\n  * Patients with HIV viral load > 400 copies/mL\n* Active Hepatitis B or Hepatitis C\n* Patients who have received a live vaccine within 30 days of the start date of the planned study therapy (with the exception of COVID-19 vaccines)\n* History of active TB (Bacillus Tuberculosis)\n* Radiation therapy within 2 weeks prior to study day 1\n* If patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\n* Women who are pregnant or breast feeding\n* Patients expecting to conceive or father children within the projected duration of the trial, starting with the visit through 180 days after the last dose of study treatment(s)\n* Prior organ transplantation including allogenic stem-cell transplantation\n* Active infection requiring systemic therapy\n* Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v5.0 Grade ≥ 3)\n* Patients with prior history of interstitial lung disease and clinically significant pulmonary compromise, including those who have a requirement for supplemental oxygen use to maintain adequate oxygenation",
    "miscellaneous_criteria": ""
}